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AbstrAct
Background In the RAISE trial, ramucirumab+leucovorin/
fluorouracil/irinotecan (FOLFIRI) improved the median 
overall survival (mOS) of patients with previously treated 
metastatic colorectal cancer versus patients treated 
with placebo+FOLFIRI but had a higher incidence of 
neutropaenia, leading to more chemotherapy dose 
modifications and discontinuations. Thus, we conducted an 
exploratory post-hoc analysis of RAISE and a retrospective, 
observational analysis of electronic medical record 
(EMR) data to determine and verify the association of 
neutropaenia, baseline absolute neutrophil count (ANC) 
and survival.
Methods The RAISE analysis used the study safety 
population (n=1057). IMS Health Oncology Database 
(IMS EMR) was the source for the real-world data set 
(n=617).
Results RAISE patients with treatment-emergent 
neutropaenia had improved mOS compared with those 
without (ramucirumab arm: 16.1 vs 10.7 months, 
HR=0.57, p<0.0001; placebo arm: 12.7 vs 10.7 months, 
HR=0.76, p=0.0065). RAISE patients with low ANC versus 
high baseline ANC also had longer mOS (ramucirumab 
arm: 15.2 vs 8.9 months, HR=0.49, p<0.0001; placebo 
arm: 13.2 vs 7.3 months, HR=0.50, p<0.0001). The results 
were similar for IMS EMR low versus high baseline ANC 
(bevacizumab+FOLFIRI patients: 14.9 vs 7.7 months, 
HR=0.59, p<0.0001; FOLFIRI alone: 14.6 vs 5.4 months, 
HR=0.37, p<0.0001). Patients in the RAISE trial with low 
baseline ANC were more likely to develop neutropaenia 
(OR: ramucirumab arm=2.62, p<0.0001; placebo 
arm=2.16, p=0.0003).
Conclusion Neutropaenia during treatment, and 
subsequent dose modifications or discontinuations, do not 
compromise treatment efficacy. Baseline ANC is a strong 
Key questions
What is already known about this subject?
 ► Historically, the second-line treatment choice in 
patients with metastatic colorectal cancer (mCRC) 
has depended on the treatment administered as 
first-line therapy.
 ► However, ideally the decisions of which therapy  
to prescribe as second-line treatment and  
when to discontinue or change treatment, based  
on a lack of efficacy and/or high toxicity, would be  
informed from reliable predictive or prognostic 
biomarkers.
 ► Although therapy options for mCRC have  
increased, valuable predictive and prognostic  
markers of treatment efficacy remain largely  
unidentified.
 ► Neutropaenia has previously been characterised  
as a prognostic factor for cancer treatment  
efficacy.
What does this study add?
 ► An association between neutropaenia incidence 
and better overall survival was determined in 
patients with mCRC from the ramucirumab RAISE 
trial.
 ► Baseline absolute neutrophil count was confirmed 
as a prognostic marker for survival in previously 
treated patients with colorectal cancer in a 
post-hoc analysis of the RAISE trial and confirmed 
in a prespecified analysis using electronic medical 
record data.
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prognostic factor for survival and is associated with treatment-emergent 
neutropaenia in the analysed population.
Trial registration number NCT01183780, Results.
InTRoduCTIon
Although remarkable improvements have been achieved 
for the treatment of patients with metastatic colorectal 
cancer (mCRC) in the last decade, the 5-year survival rate 
is still only 11%.1 Although chemotherapy remains the 
foundation of medical management of mCRC,2 targeted 
therapies, such as those that inhibit the epidermal growth 
factor (EGFR) or vascular endothelial growth factor 
(VEGF) pathways, are a valuable addition to first-line 
and second-line options.3 Ramucirumab is a recombi-
nant human IgG1 monoclonal antibody receptor antag-
onist designed to block the ligand-binding site of VEGF 
receptor-2. Bevacizumab is a humanised monoclonal anti-
body that inhibits VEGF signalling by binding directly to 
circulating VEGF-A. Both of these therapies have been 
approved for use in specific populations of patients with 
mCRC.4 5 Historically, the second-line treatment choice 
in patients with mCRC has depended on the treatment 
administered as first-line therapy.6 However, ideally the 
decisions of which therapy to prescribe as second-line 
treatment and when to discontinue or change treat-
ment, based on a lack of efficacy and/or high toxicity, 
would be informed from reliable predictive or prognostic 
biomarkers. Although therapy options for mCRC have 
increased, valuable predictive and prognostic markers 
of treatment efficacy remain largely unidentified. The 
National Comprehensive Cancer Network recommends 
screening for three particular mutations in patients with 
colorectal cancer (CRC)7: RAS mutations as predictive 
biomarkers of the ineffectiveness of anti-EGFR therapy8 9; 
BRAF mutations as an established prognostic indicator10; 
and the loss of normal mismatch repair (MMR) proteins 
and resulting microsatellite instability (MSI), which 
impart an MMR-deficient/MSI-high phenotype that is 
associated with improved outcomes and responsiveness 
to immunotherapy.11 
Most patients with mCRC will not have curative options, 
and a balance between treatment efficacy and tolera-
bility is an important component of treatment selection.6 
Systemic chemotherapies used for the treatment of mCRC 
have well-defined side effect profiles, including gastro-
intestinal toxicity, neurotoxicity and myelotoxicity.12 
Targeted therapies can contribute additional complica-
tions; for example, some of the most frequent adverse 
events (AEs) attributed to VEGF inhibitors include hyper-
tension and proteinuria.4 5 13 14 In several retrospective 
analyses of mCRC trials, the incidence of haematological 
toxicities, such as neutropaenia, thrombocytopaenia and 
anaemia, have been characterised as potential prognostic 
indicators of efficacy.15 16 Therefore, special attention to 
treatment toxicity and AEs beyond patients’ safety may 
be advantageous for determining subsequent regimens 
and establishing prognostic indicators.
In the RAISE study, ramucirumab+leucovorin/fluo-
rouracil/irinotecan (FOLFIRI) improved the overall 
survival (OS) and progression-free survival of patients 
with previously treated mCRC compared with patients 
treated with placebo plus FOLFIRI.14 However, some AEs 
were more frequent in the ramucirumab+FOLFIRI group, 
particularly neutropaenia (any grade): 58.8% in the 
ramucirumab arm vs 45.6% in the placebo arm.14 This 
increase in neutropaenia led to more chemotherapy dose 
reductions, omissions, delays and discontinuations in the 
ramucirumab arm (47.8% vs 36.6%), which were associ-
ated with lower chemotherapy relative dose intensities 
(online supplementary table S1) and raised the concern 
for treatment efficacy in patients with neutropaenia. This 
led us to conduct a post-hoc, exploratory analysis of the 
RAISE patients’ OS based on whether they had treat-
ment-emergent neutropaenia,17 followed by an analysis of 
the relationship between neutropaenia and baseline abso-
lute neutrophil count (ANC). To validate these results, 
a real-world evidence, retrospective, observational study 
was subsequently conducted to determine the association 
between baseline ANC and OS with or without a VEGF 
inhibitor (ie, bevacizumab) plus FOLFIRI treatment in 
a second-line CRC population using electronic medical 
record (EMR) data.18 The exploratory and confirmatory 
results from the CRC populations are reported.
PaTIenTs and MeThods
RaIse study design and patients
The study design and patient criteria for the RAISE study 
have been published previously.14 Briefly, 1072 patients 
with mCRC with disease progression during or after 
first-line treatment with oxaliplatin, a fluoropyrimidine, 
and bevacizumab were randomised 1:1 to receive 8 mg/
kg intravenous second-line ramucirumab in combina-
tion with FOLFIRI (ramucirumab arm) or placebo plus 
FOLFIRI (placebo arm) every 2 weeks (NCT01183780). A 
post-hoc, exploratory analysis of patients was conducted 
to determine the effect of neutropaenia on clinical 
outcomes. Patients from the safety population, who 
received at least one dose of study drug (n=1057), were 
grouped by those who developed any-grade neutropaenia 
after the initiation of study treatment (n=552/1057, 
52.2% of the total RAISE patients) and those who did 
not (n=505/1057, 47.8% of the total RAISE patients). 
Neutropaenia was defined as ANC<1.5 x 109/L. Patients 
were stratified by low/high baseline ANC (≤5.6 or >5.6 
Kcells/µL, the highest quartile).
Key questions
how might this impact on clinical practice?
 ► The treatment effect of ramucirumab in patients with neutropaenia 
with mCRC is unlikely to be compromised despite lower 
chemotherapy dose intensity.
 ► Furthermore, a simple neutrophil cell count at baseline is a strong 
prognostic factor for survival in the analysed populations.
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Real-world evidence, patients and hypothesis testing
The IMS Health Oncology Database (IMS EMR), an 
integrated database of EMR from more than 600 000 
de-identified patients with cancer who received care 
from approximately 550 providers in all 50 US states 
(with the southern region over-represented), was used 
as the data source for the real-world evidence, confirm-
atory study. Patients were included if they fulfilled the 
following criteria: ≥18 years old with CRC (Interna-
tional Classification of Diseases-9 code 153.x, 154.0 or 
154.1); began second-line fluoropyrimidine and irino-
tecan (±bevacizumab) in 2007–2013 (index date), 
following first-line fluoropyrimidine and oxaliplatin 
(±any biologic); ≥1 ANC measure(s) in the 60 days prior 
to initiation of second-line therapy; and ≥1 health system 
interaction in the 3 months preceding their last inter-
action (important for best results using the OS proxy, 
which uses time of last interaction as an estimate of 
death date for patients).
For the IMS EMR analysis, the prespecified top quar-
tile cut-off for baseline ANC was 5.5 x 109/L. Patients 
were stratified by second-line bevacizumab use (yes or 
no) and low/high baseline ANC (<5.5 or ≥5.5 x 109/L). 
Prespecified hypotheses included HRs for patients 
receiving bevacizumab by ANC level, HRs for patients 
not receiving bevacizumab by ANC level and the inter-
action between the groups. An overall study alpha 
of 0.05 was maintained using the Bonferroni-Holm 
procedure.19
statistical analyses
For the RAISE retrospective analysis, patients with and 
without neutropaenia and patients with high and low 
baseline ANC were compared by treatment arm. ORs 
were calculated as odds of neutropaenia=yes in low ANC 
group/odds of neutropaenia=yes in high ANC group, 
with exact confidence limits and percentages based on 
the total number of patients in each ANC group. P values 
were based on Fisher’s exact test. OS was analysed using 
the Kaplan-Meier (KM) method, a Cox proportional 
hazards model and a log-rank test. The significance level 
for interaction tests was p<0.1.
In the retrospective observational study, propensity 
scores adjusted for gender, age, disease stage, Eastern 
Cooperative Oncology Group performance status, base-
line body mass index and duration of first-line treatments 
(<6 vs ≥6 months) were estimated using logistic regres-
sion. Propensity score matching (up to 1:3) was applied 
to adjust baseline difference between cohort pairs (beva-
cizumab/high ANC vs bevacizumab/low ANC, no beva-
cizumab/high ANC vs no bevacizumab/low ANC). KM 
analyses and Cox proportional hazards models were used 
to estimate the median OS and HR between cohorts. OS 
from the start of second-line therapy was approximated 
by time to the last health system interaction. The adjusted 
covariates in Cox models were as listed above in the 
propensity score model.
ResulTs
RaIse post-hoc, exploratory analyses
RAISE patient population
Patients with and without neutropaenia were compared 
by treatment arm; any-grade neutropaenia occurred in 
58.8% (311/529) of ramucirumab patients (grade ≥3, 
38.4%) vs 45.6% (241/528) of placebo patients (grade ≥3, 
23.3%). The baseline demographics and disease charac-
teristics of the RAISE patients with and without any-grade 
neutropaenia that developed after the initiation of study 
treatment are shown in table 1. Baseline characteristics 
were generally balanced between the arms, but the rates of 
neutropaenia for both ramucirumab and placebo patients 
were considerably different depending on certain baseline 
characteristics, including time to progression (<6 vs ≥6 
months, ramucirumab: 46.4% vs 62.6%; placebo: 29.1% 
vs 50.9%), race (white vs Asian, ramucirumab: 53.5% vs 
80.0%; placebo: 43.3% vs 59.2%) and gender (male vs 
female, ramucirumab: 54.2% vs 64.2%; placebo: 42.1% vs 
51.2%). The median time to the first neutropaenic event in 
the ramucirumab arm was 2.6 weeks (range 0.9–41.7 weeks) 
for any-grade neutropaenia and 3.0 weeks (range 1.3–107.0 
weeks) for grade ≥3 neutropaenia; in the placebo arm, it 
was 3.5 weeks (range 0.0–75.2 weeks) and 3.9 weeks (range 
0.9–37.0 weeks), respectively. Among patients who had at 
least one neutropaenic event, 83% developed neutropaenia 
within 2 months of starting treatment.
OS by patient neutropaenia incidence
In both the ramucirumab and placebo arms, RAISE 
patients with treatment-emergent neutropaenia had 
longer median OS compared with patients who did not 
experience neutropaenia on study (figure 1). The median 
OS for patients with treatment-emergent neutropaenia 
compared with those without was 16.1 vs 10.7 months for 
ramucirumab (HR=0.57, 95% CI 0.46 to 0.70, p<0.0001) 
and 12.7 vs 10.7 months for placebo (HR=0.76, 95% CI 
0.62 to 0.93, p=0.0065). In comparing treatment arms 
based on neutropaenia incidence, the HR of ramucirum-
ab-treated versus placebo patients with any-grade neutro-
paenia was 0.79 (95% CI 0.64 to 0.96, p=0.02), whereas 
patients who did not experience a neutropaenic event had 
an HR of 1.05 (95% CI 0.86 to 1.28, p=0.646). The interac-
tion between neutropaenia and treatment was significant 
(p=0.0546). Similar efficacy was detected in patients with 
grade ≥2 or ≥3 neutropaenia (median OS grade ≥2: ramu-
cirumab=15.7 months, placebo=13.1 months; grade ≥3: 
ramucirumab=15.7 months, placebo=12.7 months).
Because neutropaenic events are likely to increase with 
time, it is possible that the longer survival of patients with 
neutropaenia is solely due to a survival bias—patients with 
very short survival are unlikely to develop neutropaenia. 
Therefore, an analysis was conducted in patients who 
survived for at least 2 months. A comparable efficacy trend 
was detected in these patients; the median OS for any-grade 
neutropaenia versus no neutropaenia within the first 2 
months was 15.5 vs 12.9 months for ramucirumab (HR=0.75, 
95% CI 0.61 to 0.93, p=0.0073) and 12.3 vs 12.0 months for 
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  Europe 121 112 51.9 95 137 40.9
  North America 81 57 58.7 60 79 43.2
  Other regions 109 49 69.0 86 71 54.8
Time to progression after first-line therapy
  <6 months 58 67 46.4 37 90 29.1
  ≥6 months 253 151 62.6 204 197 50.9
K-Ras status
  Mutant 156 110 58.6 110 149 42.5
  Wild-type 155 108 58.9 131 138 48.7
Gender
  Male 155 131 54.2 135 186 42.1
  Female 156 87 64.2 106 101 51.2
Age (years)
  <65 187 133 58.4 133 183 42.1
  ≥65 124 85 59.3 108 104 50.9
Race
  White 214 186 53.5 174 228 43.3
  Asian 88 22 80.0 61 42 59.2
  Other 7 10 41.2 6 12 33.3
  Missing 2 0 100.0 0 5 0.0
ECOG PS
  0 160 100 61.5 119 137 46.5
  1 149 116 56.2 121 149 44.8
  2 1 0 100.0 0 1 0.0
  3 0 0 0.0 1 0 100.0
  Missing 1 2 33.3 0 0 0.0
Number of metastatic sites
  1 95 76 55.6 68 87 43.9
  2 130 73 64.0 86 106 44.8
  ≥3 86 69 55.5 87 94 48.1
Liver-only metastasis
  No 265 171 60.8 204 231 46.9
  Yes 46 47 49.5 37 56 39.8
Site of primary tumour
  Colon 209 141 59.7 169 183 48.0
  Colorectal 3 1 75.0 3 4 42.9
  Rectum 99 76 56.6 69 100 40.8
Carcinoembryonic antigen
  <200 μg/L 232 152 60.4 180 208 46.4
  ≥200 μg/L 61 46 57.0 46 58 44.2
  Missing 18 20 47.4 15 21 41.7
Baseline ANC (×109/L)
  Median (range) 3.8 (1–26) 4.7 (1–15) – 3.9 (1–13) 4.6 (2–29) – 
ANC, absolute neutrophil count; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRI, leucovorin/fluorouracil/irinotecan.
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placebo (HR=0.88, 95% CI 0.72 to 1.09, p=0.2326). A treat-
ment arm comparison between ramucirumab and placebo 
demonstrated that patients with any-grade neutropaenia 
within the first 2 months had an HR of 0.79 (95% CI 0.63 to 
0.99, p=0.0401); patients with no neutropaenia within the 
first 2 months had an HR of 0.93 (95% CI 0.77 to 1.13, 
p=0.4531). These analyses suggest that survival bias is not 
the sole cause of the relationship between neutropaenia 
and survival.
OS and neutropaenia association with patient baseline ANC
OS was analysed in RAISE patients from both the ramu-
cirumab and placebo arms by low/high baseline ANC 
(≤5.6 or >5.6 x 109/L). Patients taking ramucirumab with 
low ANC had a median OS of 15.2 months, whereas patients 
taking ramucirumab with high ANC had a median OS of 8.9 
months (HR=0.49, 95% CI 0.39 to 0.61, p<0.0001). Placebo 
patients showed a similar trend, with a median OS of 13.2 
months with low ANC and a median OS of 7.3 months 
with high ANC (HR=0.50, 95% CI 0.40to 0.63, p<0.0001) 
(figure 2). There was little evidence for an interaction effect 
between the treatment and ANC group (p=0.8827); the HR 
for ramucirumab and low ANC versus placebo and low 
ANC was 0.84 (95% CI 0.71 to 0.99, p=0.0382), and the HR 
for ramucirumab and high ANC versus placebo and high 
ANC was 0.88 (95% CI 0.67 to 1.15, p=0.3425).
Baseline ANC was additionally analysed to determine 
whether there was an association with treatment-emer-
gent neutropaenia in the RAISE patients. Ramucirumab 
patients with low baseline ANC had a 64.7% chance of 
developing neutropaenia, whereas ramucirumab patients 
with high baseline ANC had a 41.2% chance (OR=2.62, 
95% CI 1.75 to 3.92, p<0.0001). Placebo patients demon-
strated a similar trend; patients with low baseline ANC had 
a 50.3% chance of developing neutropaenia, and those 
Figure 2 Patients with low baseline ANC had improved overall survival in RAISE trial. ANC, absolute neutrophil count; 
FOLFIRI, leucovorin/fluorouracil/irinotecan; PBO, placebo; RAM, ramucirumab. 
Figure 1 Patients with treatment-emergent neutropaenia had improved overall survival in RAISE trial. FOLFIRI, leucovorin/
fluorouracil/irinotecan; PBO, placebo; RAM, ramucirumab.
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with high baseline ANC had a 31.8% chance (OR=2.16, 
95% CI 1.43 to 3.28, p=0.0003). Overall, RAISE patients 
with low baseline ANC had a higher likelihood of having 
neutropaenia and better outcomes.
Validation of anC effects in a retrospective, observational 
study with real-world data
IMS EMR patient population
Data from patients with CRC initiating second-line 
therapy from 2007 to 2013 were obtained from the IMS 
EMR. A total of 617 patients met the entry criteria for this 
study and could be matched by propensity scores (online 
supplementary table S2).
Baseline demographics and use of biologics in the 
real-world population of CRC patients at the start of 
second-line treatment with FOLFIRI with or without beva-
cizumab are listed in table 2. Patients had a median age 
of 59 years (range 20–82 years) and were mostly Cauca-
sian (67%) and male (57%). Most of the patients also had 
stage IV CRC at diagnosis (74%). Bevacizumab treatment 
in first-line and second-line therapy was the predominant 
biologic regimen (48%); 14% were given bevacizumab 
only in first-line treatment, 23% were given bevacizumab 
only in second-line treatment, and 14% did not receive 
bevacizumab in either first-line or second-line therapy.
OS by patient baseline ANC
OS was assessed in individual patients by low/high (<5.5 or 
≥5.5 x 109/L) baseline ANC values (online supplemen-
tary figure S1). Low baseline ANC with or without bevaci-
zumab resulted in a longer median OS versus high base-
line ANC. With bevacizumab, the median OS was 14.9 
months for patients with low baseline ANC vs 7.7 months 
for those with high baseline ANC (HR=0.59, 95% CI 
0.47 to 0.74, p<0.0001); without bevacizumab, the median 
OS was 14.6 months for patients with low baseline ANC vs 
5.4 months for those with high baseline ANC (HR=0.37, 
95% CI 0.25 to 0.53, p<0.0001) (figure 3). There was also 
a modest interaction effect between bevacizumab treat-
ment and baseline ANC (p=0.012), indicating greater 
bevacizumab benefit in the high baseline ANC group.
dIsCussIon
The RAISE trial reported a higher incidence of neutro-
paenia following ramucirumab+FOLFIRI treatment in 
patients with mCRC, but patients still demonstrated signif-
icantly improved survival.14 In the current post-hoc anal-
ysis of the RAISE trial, any-grade neutropaenia was associ-
ated with improved OS versus no neutropaenia, regardless 
of treatment arm. Furthermore, the likelihood of having 
treatment-emergent neutropaenia was higher in patients 
with low baseline ANC, and the survival difference was 
higher in the low versus high baseline ANC compar-
ison than in the neutropaenia versus no neutropaenia 
comparison. Because baseline ANC is also earlier tempo-
rally, this suggests that baseline ANC is the better prog-
nostic marker of patient outcomes, although it does not 
exclude the possibility that treatment-emergent neutro-
paenia has additional independent prognostic value. In 
addition, the stronger association between baseline ANC 
and survival suggests that neutropaenia is not itself bene-
ficial, but rather is associated with survival because of 
the poorer prognosis of high baseline ANC patients and 
the lower likelihood that those patients experience large 
enough decreases in neutrophil count during treatment 
to become neutropaenic.
Table 2 Real-world demographics and baseline 







Gender, male, % of patients 57
Age, years
  Median [min, max] 59 [20, 82]
Race (of 63% with known race), % of patients
  Caucasian 67
  African–American 26
  Hispanic 2
  Asian 1
  Other 4
Disease stage at diagnosis (of 67% with known stage), % of 
patients
  Stage IV 74
ECOG PS at index (of 66% with known ECOG PS), % of 
patients
  0/1 63
Baseline ANC, median [min, max] 4.1 [1, 21]
Tumour location, % of patients
  Colon 83
  Rectum 17
Biologic treatment, % of patients
First-line Second-line
  Bevacizumab Bevacizumab 48
  No biologic Bevacizumab 23
  Bevacizumab No biologic 14
  Cetuximab Bevacizumab 1
  Cetuximab No biologic <1
  No biologic No biologic 14
Time between first-line and second-line treatment, % of 
patients
  <6 months 37
BMI<20, % of patients 8
ANC, absolute neutrophil count; BMI, body mass index; ECOG 
PS, Eastern Cooperative Oncology Group performance status; 
FOLFIRI, leucovorin/fluorouracil/irinotecan; max, maximum; min, 
minimum.
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Neutropaenia, neutrophil counts and neutro-
phil-to-lymphocyte ratio have previously been character-
ised as prognostic markers for survival in CRC.15 16 20 21 
The rationale for why neutrophil levels are associated 
with survival is unclear. Generally, inflammation is known 
to drive tumourigenesis, and neutrophils are active 
contributors to the tumour inflammatory milieu.22 
Although neutropaenia has previously been described as 
a surrogate marker for antitumour cytotoxicity of chemo-
therapy,16 the complete biological mechanism(s) remains 
uncertain. Neutrophils have been linked to promoting 
angiogenesis,23–25 driving tumour growth,21 26 activating 
the stress response and accelerating metastatic disease 
progression.24 Inflammation has also been associated with 
p53 mutations,27 which have been suggested to increase 
resistance to both 5-fluorouracil and irinotecan.28 29 More 
work in this area would be valuable, perhaps considering 
associations between comorbidities and the baseline 
factors associated with differences in neutrophil levels 
such as race, gender and time to progression.
In this study, we saw a weak, apparent, predictive effect 
in the EMR analysis, indicating greater benefit for bevaci-
zumab (vs no bevacizumab)-treated patients in the high 
baseline ANC group. By contrast, the RAISE study showed 
less evidence for a predictive effect, and the significant 
result in the neutropaenia group trended towards more 
benefit of ramucirumab versus placebo (corresponding 
to the low baseline ANC group). Other studies have also 
suggested associations between either neutropaenia 
or baseline ANC and cancer treatment effectiveness, 
including neutropaenia that occurred early in the course 
of treatment as a positive predictive factor for TAS-102 
efficacy in CRC30 and a baseline ANC>6.0 Kcells/µL as a 
negative prognostic factor for patient survival, yet a posi-
tive predictive factor for bevacizumab efficacy.31 Further 
study will be necessary to confirm these results and to 
determine whether differences may be drug-specific or 
relate to differences between treatment-emergent neut-
ropaenia and baseline ANC.
There are several limitations to the current anal-
yses. For the post-hoc analysis of RAISE patients, the 
results should be interpreted with caution due to the 
non-randomised nature of the subgroup analysis. 
With regard to the treatment arm comparisons in 
particular, defining subgroups based on a postrando-
misation factor confounds the very definition of such 
subgroups with treatment effect. The clinical implica-
tions of the neutropaenia data alone are also limited 
because neutropaenia only occurs postinitiation of 
therapy. Furthermore, longer time on therapy implied 
increased probability of developing neutropaenia, 
potentially confounding the analyses by associating 
longer survival with neutropaenia; however, as previ-
ously mentioned, most of the neutropaenic events 
(83%) occurred within the first 2 months of treatment, 
and OS results similar to those in the entire study by 
neutropaenic status were detected early, in patients 
who survived at least 2 months and had or did not 
have neutropaenia during that period. For the analysis 
of real-world evidence, EMR data can prove useful for 
testing exploratory hypotheses generated in clinical 
trials, but significant data were missing, likely not at 
random, and key fields such as line of therapy were 
derived. Treatment choices are not random in the 
real world and may bias comparisons between groups. 
Additionally, the observational results presented here 
are specific to the population studied (US communi-
ty-based EMR, weighted towards the south) and may 
not be generalisable. In the EMR analysis, the time to 
last interaction was used as a proxy for survival time 
and therefore understates OS. Moreover, high baseline 
ANC was defined based on a prespecified cut-point 
and may not have optimised understanding of patient 
differences. Lastly, all of our patients in both studies 
Figure 3 IMS EMR patients with low baseline ANC had improved overall survival. ANC, absolute neutrophil count; EMR, 
electronic medical record. 
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received FOLFIRI, and it is not clear if the current 
results are generalisable to patients receiving other 
therapies.
ConClusIon
Study populations from the RAISE clinical trial and 
from the IMS EMR database demonstrated a signifi-
cant relationship between baseline ANC and survival. 
Treatment-emergent neutropaenia appears to occur 
most commonly in a population with lower baseline 
ANC, yet does not lead to poorer outcomes. Overall, a 
simple neutrophil cell count at baseline is suggested to 
be strong prognostic factor for survival in the analysed 
population.
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